Alger Associates reports 1.27M FBRX shares

Alger Associates, Inc. amended its Schedule 13G to report beneficial ownership of 1,272,596 shares of Forte Biosciences common stock, equal to 10.2% of the class.

Rhea-AI Filing Summary

Alger Associates, Inc. amended its Schedule 13G to report beneficial ownership of 1,272,596 shares of Forte Biosciences common stock, equal to 10.2% of the class. The filing states these shares are held in open-end investment companies and managed accounts of Fred Alger Management, LLC, a wholly owned subsidiary of Alger Group Holdings, LLC, which in turn is a subsidiary of Alger Associates, Inc. The filing lists sole voting power of 1,268,303 shares and sole dispositive power of 1,272,596 shares. Signature date is 05/15/2026.

Insights

Portfolio Governance Specialist

Report documents a >10% passive holding by an investment manager.

The filing records 1,272,596 shares (10.2%) beneficially owned by Alger Associates, held through client accounts managed by Fred Alger Management, LLC. Ownership is presented as passive investment management rather than an operating-level acquisition.

Investment managers' decisions about client accounts will determine any future disposals; cash‑flow treatment and planned dispositions are not stated in the excerpt.

Key Figures

Beneficial ownership: 1,272,596 shares Percent of class: 10.2% Sole voting power: 1,268,303 shares +3 more

6 metrics

Beneficial ownership 1,272,596 shares Amount beneficially owned (Item 4(a))

Percent of class 10.2% Percent of class (Item 4(b))

Sole voting power 1,268,303 shares Item 4(c)(i)

Sole dispositive power 1,272,596 shares Item 4(c)(iii)

CUSIP 34962G208 Common Stock identifier at top of the filing

Signature date 05/15/2026 Signed by Hal Liebes / Secretary

Key Terms

beneficially owned, sole dispositive power, open-end investment companies, managed accounts

4 terms

beneficially owned regulatory

"Amount beneficially owned: 1,272,596 (b) | Percent of class: 10.2%"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"(iii) Sole power to dispose or to direct the disposition of: 1,272,596"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

open-end investment companies financial

"beneficially owned by one or more open-end investment companies or other managed accounts"

managed accounts financial

"managed accounts that are investment management clients of Fred Alger Management, LLC"

Managed accounts are collections of investments owned by an individual or institution but run day-to-day by a professional who buys, sells and allocates assets according to an agreed plan. They matter to investors because they provide tailored oversight, active risk control and potential tax efficiency—like hiring a personal chef to manage your diet—while fees and the manager’s skill directly affect returns.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Alger Associates report in FBRX?

Alger Associates reports beneficial ownership of 1,272,596 shares, or 10.2% of the class. The filing states sole voting power of 1,268,303 shares and sole dispositive power of 1,272,596 shares, with holdings held in client investment vehicles managed by Fred Alger Management, LLC.

Are these shares held for Alger Associates or clients of Fred Alger Management?

The filing says the shares are held in open-end investment companies and managed accounts that are clients of Fred Alger Management, LLC. Fred Alger Management is a 100% owned subsidiary of Alger Group Holdings, LLC, which is a 100% owned subsidiary of Alger Associates, Inc.

Does the filing indicate any planned sale or purchase of FBRX shares?

The excerpt does not disclose any planned purchases or sales. It provides beneficial ownership and voting/dispositive power figures but does not state intentions, planned transactions, or methods for any future disposition in the provided text.

What voting and dispositive powers does Alger report for the shares?

Alger reports sole voting power for 1,268,303 shares and sole dispositive power for 1,272,596 shares. Shared voting and dispositive powers are reported as zero in the provided excerpt, matching the listed beneficial ownership total.

What dates and identifiers appear in the filing?

The filing lists CUSIP 34962G208 and a date entry of 03/31/2026 near the header. The signature block is dated 05/15/2026, and the filer is identified as Alger Associates, Inc. with an address for Fred Alger Management provided in the text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:05 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

34962G208

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

Alger Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,268,303.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,272,596.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

624,286.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247
Item 2.
(a)	Name of person filing: Alger Associates, Inc.
(b)	Address or principal business office or, if none, residence: 100 Pearl Street, 27th Floor, New York, NY 10004
(c)	Citizenship: New York
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,272,596
(b)	Percent of class: 10.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,268,303
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,272,596
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC ("FAM"), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC ("AGH"), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit A.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alger Associates, Inc.

Signature:	/s/ Hal Liebes
Name/Title:	Hal Liebes / Secretary
Date:	05/15/2026